CL2021002397A1 - Derivados de insulina sensibles a la glucosa - Google Patents

Derivados de insulina sensibles a la glucosa

Info

Publication number
CL2021002397A1
CL2021002397A1 CL2021002397A CL2021002397A CL2021002397A1 CL 2021002397 A1 CL2021002397 A1 CL 2021002397A1 CL 2021002397 A CL2021002397 A CL 2021002397A CL 2021002397 A CL2021002397 A CL 2021002397A CL 2021002397 A1 CL2021002397 A1 CL 2021002397A1
Authority
CL
Chile
Prior art keywords
insulin derivatives
glucose
sensitive insulin
diabetes
prevention
Prior art date
Application number
CL2021002397A
Other languages
English (en)
Inventor
Henning Thøgersen
Thomas Hoeg-Jensen
Carsten Behrens
Emiliano Cló
Martin Werner Borchsenius Münzel
Per Sauerberg
Thomas Kruse
Jane Spetzler
Ulrich Sensfuss
Claudia Ulrich Hjørringgaard
Vojtech Balšánek
Zuzana Drobnáková
Ladislav Drož
Miroslav Havránek
Vladislav Kotek
Milan Štengl
Ivan Šnajdr
Hana Vánová
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CL2021002397A1 publication Critical patent/CL2021002397A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a nuevos derivados de insulina y su uso en el tratamiento o la prevención de afecciones médicas relacionadas con la diabetes. Los derivados de insulina son sensibles a la glucosa y presentan unión a la albúmina sensible a la glucosa. La invención también se refiere a nuevos productos intermedios. Por último, la invención proporciona una composición farmacéutica que comprende los derivados de insulina de la invención y el uso de dicha composición en el tratamiento o la prevención de afecciones médicas relacionadas con la diabetes.
CL2021002397A 2019-03-29 2021-09-14 Derivados de insulina sensibles a la glucosa CL2021002397A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19166131 2019-03-29
EP19174671 2019-05-15

Publications (1)

Publication Number Publication Date
CL2021002397A1 true CL2021002397A1 (es) 2022-04-22

Family

ID=70189906

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002397A CL2021002397A1 (es) 2019-03-29 2021-09-14 Derivados de insulina sensibles a la glucosa

Country Status (16)

Country Link
US (1) US20220184184A1 (es)
EP (1) EP3946363A2 (es)
JP (2) JP6795718B2 (es)
KR (1) KR102507156B1 (es)
CN (1) CN113646329A (es)
AU (1) AU2020255195A1 (es)
BR (1) BR112021016782A2 (es)
CA (1) CA3131832A1 (es)
CL (1) CL2021002397A1 (es)
CO (1) CO2021013251A2 (es)
IL (1) IL285664A (es)
MX (1) MX2021010988A (es)
PE (1) PE20220380A1 (es)
SG (1) SG11202108958PA (es)
TW (2) TWI717245B (es)
WO (1) WO2020201041A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022543586A (ja) * 2019-07-31 2022-10-13 サーマリン インコーポレイテッド グルコース調節型立体配座スイッチを有するインスリン類似体
GB2610490A (en) * 2020-03-31 2023-03-08 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols
TW202237188A (zh) * 2020-11-19 2022-10-01 美商普羅托莫科技公司 芳族含硼化合物及胰島素類似物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930001305B1 (ko) * 1989-10-19 1993-02-25 니뽕 유우시 가부시끼가이샤 당 응답형 고분자 복합체(Polymer Complexes of Sugar Response Type)
WO2003048195A2 (en) * 2001-12-02 2003-06-12 Novo Nordisk A/S Glucose dependant release of insulin from glucose sensing insulin derivatives
US9260502B2 (en) * 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
WO2011000823A1 (en) * 2009-06-30 2011-01-06 Novo Nordisk A/S Insulin derivatives
US9867869B2 (en) * 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
US11052133B2 (en) * 2015-05-06 2021-07-06 Protomer Technologies, Inc. Glucose responsive insulins
BR112018002416A2 (pt) 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
US11186595B2 (en) * 2017-11-09 2021-11-30 Novo Nordisk A/S Glucose-sensitive albumin-binding derivatives
WO2019204206A1 (en) * 2018-04-16 2019-10-24 Chou Danny Hung Chieh Glucose-responsive insulin

Also Published As

Publication number Publication date
AU2020255195A1 (en) 2021-10-14
CO2021013251A2 (es) 2022-01-17
CN113646329A (zh) 2021-11-12
US20220184184A1 (en) 2022-06-16
WO2020201041A2 (en) 2020-10-08
BR112021016782A2 (pt) 2021-11-30
JP2020164525A (ja) 2020-10-08
WO2020201041A3 (en) 2020-11-19
KR102507156B1 (ko) 2023-03-09
PE20220380A1 (es) 2022-03-18
KR20210148143A (ko) 2021-12-07
CA3131832A1 (en) 2020-10-08
EP3946363A2 (en) 2022-02-09
TW202112397A (zh) 2021-04-01
JP2022527732A (ja) 2022-06-06
MX2021010988A (es) 2021-10-01
IL285664A (en) 2021-10-31
SG11202108958PA (en) 2021-09-29
TWI717245B (zh) 2021-01-21
JP6795718B2 (ja) 2020-12-02
TW202102253A (zh) 2021-01-16

Similar Documents

Publication Publication Date Title
CL2021002397A1 (es) Derivados de insulina sensibles a la glucosa
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
UY29020A1 (es) Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina, procedimientos para su preparacinn y su uso.-
BR112018003845A2 (pt) auxiliares cirúrgicos com medicamentos afetados por materiais ativadores
AR116605A1 (es) Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
BR112015019430A8 (pt) composições farmacêuticas para a cicatrização de ferimentos e uso das mesmas
CY1119850T1 (el) Χρηση της μετφορμινης σε συνδυασμο με ενεργοποιητη γλυκοκινασης και συνθεσεων που περιλαμβανουν μετφορμινη και ενεργοποιητη γλυκοκινασης
CL2009000757A1 (es) Compuestos derivados de 6,8,2´-tris-(isobut-2-en-1-il)-diosmetina; procedimientos para su elaboracion; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades venosas cronicas, sindrome post-trombotico, complicaciones vasculares ligadas a la diabetes, entre otras.
DOP2010000408A (es) Compuestos quimicos 251
CY1114703T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα (1s)-1,5-ανυδρο-1-[5-(4-αιθοξυβενζυλ)-2-μεθοξυ-4-μεθυλφαινυλ]-1-θειο-d-γλυκιτολη και μετφορμινη και χρησεις αυτης στη θεραπεια διαβητη
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
UY28726A1 (es) N-ciclohexilimidazolinonas sustituidas.procedimientos para su preparación y su uso como medicamentos.
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
BR112018003817A2 (pt) materiais auxiliares cirúrgicos com medicamentos afetados por ativadores
CL2008002356A1 (es) Sulfoxidos de piperazina-amida; sus procesos de preparacion; las composiciones farmaceuticas que los contienen; y su uso en el tratamiento de enfermedades que se modulan con agonistas lxr alfa y/o beta.
MX2021005134A (es) Nuevos conjugados citostaticos con ligandos de integrina.
CL2020000491A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.
DOP2019000296A (es) Compuesto de insulina acilada
CL2023000087A1 (es) Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
CY1115194T1 (el) Χρηση της μακρας πεντραξινης ptx3 για την προληψη ή θεραπεια ιικων ασθενειων
CY1115223T1 (el) Αντι-μελαγχολικο φαρμακο που παρασκευαζεται με υλικα camp απο τζιτζιφα
GT200000062A (es) Derivado sustituido de pirazol.
UY29846A1 (es) N-(1,3,4)-tiadiazol-2-il-bencensulfonamidas, procesos para su preparación y su uso como productos farmacéuticos
AR107560A1 (es) Compuesto que disminuye la glucosa en la sangre